CA3051665A1 - Compose d'imidazopyridazine - Google Patents

Compose d'imidazopyridazine Download PDF

Info

Publication number
CA3051665A1
CA3051665A1 CA3051665A CA3051665A CA3051665A1 CA 3051665 A1 CA3051665 A1 CA 3051665A1 CA 3051665 A CA3051665 A CA 3051665A CA 3051665 A CA3051665 A CA 3051665A CA 3051665 A1 CA3051665 A1 CA 3051665A1
Authority
CA
Canada
Prior art keywords
compound
6alkyl
group
heterocycloalkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA3051665A
Other languages
English (en)
Other versions
CA3051665C (fr
Inventor
Young Jin Ham
Seok Jong Kang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of CA3051665A1 publication Critical patent/CA3051665A1/fr
Application granted granted Critical
Publication of CA3051665C publication Critical patent/CA3051665C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un composé d'imidazopyridazine présentant une activité inhibitrice de la croissance cellulaire et une composition pharmaceutique comprenant le composé d'imidazopyridazine pour la prévention ou le traitement du cancer ou d'une tumeur. Le composé d'imidazopyridazine de formule chimique 1 selon la présente invention présente une excellente activité inhibitrice de la croissance cellulaire, et peut donc être avantageusement utilisé en tant qu'agent préventif ou thérapeutique du cancer ou d'une tumeur.
CA3051665A 2017-01-26 2018-01-23 Compose d'imidazopyridazine Active CA3051665C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2017-0012767 2017-01-26
KR1020170012767A KR102719387B1 (ko) 2017-01-26 2017-01-26 이미다조피리다진 화합물
PCT/KR2018/000982 WO2018139825A2 (fr) 2017-01-26 2018-01-23 Composé d'imidazopyridazine

Publications (2)

Publication Number Publication Date
CA3051665A1 true CA3051665A1 (fr) 2018-08-02
CA3051665C CA3051665C (fr) 2026-01-20

Family

ID=

Also Published As

Publication number Publication date
EP3575303A4 (fr) 2020-08-12
AU2018212151B2 (en) 2021-10-21
AU2018212151A1 (en) 2019-09-12
US20190389872A1 (en) 2019-12-26
EP3575303A2 (fr) 2019-12-04
US10781217B2 (en) 2020-09-22
RU2019126379A (ru) 2021-02-26
WO2018139825A2 (fr) 2018-08-02
WO2018139825A3 (fr) 2018-09-27
JP7057366B2 (ja) 2022-04-19
CN110234653A (zh) 2019-09-13
KR102719387B1 (ko) 2024-10-21
JP2020505401A (ja) 2020-02-20
CN110234653B (zh) 2022-02-08
RU2019126379A3 (fr) 2021-03-31
BR112019015400A2 (pt) 2020-03-31
EP3575303B1 (fr) 2022-07-06
RU2765099C2 (ru) 2022-01-25
ES2923387T3 (es) 2022-09-27
KR20180088113A (ko) 2018-08-03

Similar Documents

Publication Publication Date Title
US10301304B2 (en) Selective inhibitor of phosphatidylinositol 3-kinase-gamma
CN117222640A (zh) 作为fgfr抑制剂的杂环化合物及其应用
JP7200120B2 (ja) Ｍｋ２阻害剤として有用なヘテロアリール化合物
DE102013008118A1 (de) Arylchinazoline
EP3632906B1 (fr) Dérivé d'azaaryle, son procédé de préparation et son application pour une utilisation en pharmacie
CN104910137A (zh) Cdk激酶抑制剂
JP2020511468A (ja) Ｍｋ２阻害剤の重水素化アナログおよびその使用
EP3514153A1 (fr) Composé pyrimidine et son utilisation pharmaceutique
TWI822868B (zh) Ｆｇｆｒ４抑制劑、包含其的藥物組合物及其用途
TW202434561A (zh) Ripk2抑制劑及其用途
US20140038991A1 (en) Protein Kinase Inhibitors
JP2016531947A (ja) 配座固定されたＰＩ３Ｋ及びｍＴＯＲ阻害剤
AU2018212151B2 (en) Imidazopyridazine compound
EP4141004A1 (fr) Dérivé amide polycyclique servant d'inhibiteur de cdk9, son procédé de préparation et son utilisation
CA3051665C (fr) Compose d'imidazopyridazine
CN116249529A (zh) 喹唑啉衍生物及其在医药上的应用
US20250197411A1 (en) Irak4 protacs
CN116063325A (zh) 具有btk调节作用的大环化合物及其用途
WO2025088534A1 (fr) Composés hétérocycliques bicycliques utilisés en tant qu'inhibiteur de tead
TW202304908A (zh) 四氫吡啶并嘧啶化合物
WO2022152313A1 (fr) Dérivé de pyrimidine et son application pharmaceutique
CN119431316A (zh) 一种螺环化合物、药物组合物和应用
US20220213086A1 (en) Azole compounds as irak inhibitors, preparation methods and medicinal uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230103

EEER Examination request

Effective date: 20230103

EEER Examination request

Effective date: 20230103

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240809

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241230

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241230

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241230

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250106

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250401

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250401

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250722

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250723